Genetic
Next-Generation Sequencing (NGS)
Next-Generation Sequencing (NGS) is a genetic therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A2 (100.0%)
Trials by Status
completed250%
unknown125%
not_yet_recruiting125%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingnot_applicable
Initiative for Clinical Long-read Sequencing
NCT06060184
completednot_applicable
CIrCuLAting Dna ESr1 Gene Mutations Analysis
NCT03318263
completed
The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas
NCT03737591
unknown
Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node Metastasis
NCT03868215
Clinical Trials (4)
Showing 4 of 4 trials
NCT06060184Not Applicable
Initiative for Clinical Long-read Sequencing
NCT03318263Not Applicable
CIrCuLAting Dna ESr1 Gene Mutations Analysis
NCT03737591
The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas
NCT03868215
Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node Metastasis
All 4 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 4